---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Dosage"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Dosage. Topics: OptimUM-02 dose optimization arms and the selected combination dose in the registry record, OptimUM-02 randomized regimen: darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, OptimUM-01 first-line cohort: recommended phase 2 dose and delivered dose intensity, Crizotinib label: recommended dosage of 250 mg twice daily for adults with NSCLC, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/dosage"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### OptimUM-02 dose optimization arms and the selected combination dose in the registry record

> “Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.”
> “Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-2.1.2.10.1-2"></a>

### OptimUM-02 randomized regimen: darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily

> “Eligible patients were randomized 2:1 to receive either darovasertib 300 mg BID + crizotinib 200 mg BID or investigator’s choice (pembrolizumab, ipilimumab + nivolumab, or dacarbazine)”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-2.1.2.10.1-3"></a>

### OptimUM-01 first-line cohort: recommended phase 2 dose and delivered dose intensity

> “As of 28 May 2025, 44 pts with mUM and no prior systemic cancer therapy have received the recommended phase 2 dose of darovasertib 300 mg BID plus crizotinib 200 mg BID”

Source: [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf)

> “As observed in this patient population, with timely and appropriate management of these AEs, the mean delivered dose intensity of darovasertib-crizotinib was ≥80%.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.1.2.10.1-4"></a>

### Crizotinib label: recommended dosage of 250 mg twice daily for adults with NSCLC

> “The recommended dosage for adult patients with ALK- or ROS1-positive metastatic NSCLC is XALKORI capsules 250 mg orally, twice daily, with or without food until disease progression or unacceptable toxicity occurs.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.10.1-5"></a>

### Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction

| Dose reduction level for adult patients with NSCLC or IMT | Dose and schedule |
| --- | --- |
| First dose reduction | “200 mg twice daily” |
| Second dose reduction | “250 mg once daily” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

> “Permanently discontinue XALKORI capsules or pellets if unable to tolerate 250 mg taken once daily.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.10.1-6"></a>

### Crizotinib label: dosage modification for hematologic toxicities in adults

| Severity of hematologic adverse reaction in adult patients with NSCLC or IMT | Dosage modification |
| --- | --- |
| Grade 3 | “Withhold until recovery to Grade 2 or less, then resume at the same dosage.” |
| Grade 4 | “Withhold until recovery to Grade 2 or less, then resume at next lower dosage.” |

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

> “Monitor complete blood counts including differential weekly for the first month of therapy and then at least monthly, with more frequent monitoring if Grade 3 or 4 abnormalities, fever, or infection occur”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
